In a 2007 research, vinflunine and trastuzumab (an anti-HER2 antibody) were found to be a safe and efficient treatment for breast cancer cells with overexpressed HER2 genes (Yardley et al., 2010). Here, ERBB2 is linked to breast carcinoma.